Basic Information
| LncRNA/CircRNA Name | CASC2c |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | Cisplatin | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | qPCR, Western blot |
| Sample | NSCLC cells (H292, H226, H1975 and H460) and normal human lung bronchial epithelial cells BEAS-2B, cancer tissues and corresponding non-cancer tissues |
| Expression Pattern | down-regulated |
| Function Description | The results of RT-qPCR showed that CASC2c was under-expressed in NSCLC tissues and cells compared with normal adjacent lung tissues cells (p < 0.05). In addition, the CASC2c expression was remarkably correlated with TNM staging, tumor cell differentiation, lymph node metastasis, smoking and other pathological indicators of patients with NSCLC (p < 0.05). MTT and Transwell assay showed that the high-expression of CASC2c significantly reduced the proliferation and migration of NSCLC cells compared to that of the control group (p < 0.05). Western blot assay showed that the high-expressed CASC2c can decrease the expression of phosphorylated-ERK1/2 (p-ERK1/2) and ?-catenin. |
| Pubmed ID | 31300525 |
| Year | 2019 |
| Title | Effects of long non-coding RNA (lncRNA) cancer susceptibility candidate 2c (CASC2c) on proliferation, metastasis and drug resistance of non small cell lung cancer (NSCLC) cells through ERK1/2 and ?-catenin signaling pathways |
External Links
| Links for CASC2c | GenBank HGNC NONCODE |
| Links for non small cell lung cancer | OMIM COSMIC |